供应链
操作化
准备
业务
大流行
经济短缺
供应链管理
供应链风险管理
风险管理
独创性
背景(考古学)
医疗保健
2019年冠状病毒病(COVID-19)
营销
医学
经济
经济增长
服务管理
定性研究
财务
疾病
生物
管理
古生物学
认识论
社会学
传染病(医学专业)
病理
语言学
政府(语言学)
社会科学
哲学
作者
Victoria Ahlqvist,Nonhlanhla Dube,Marianne Jahre,Jin Soo Lee,Tsegaye Melaku,Andreas Farstad Moe,Max Olivier,Kostas Selviaridis,Joe Viana,Christine Aardal
标识
DOI:10.1108/ijpdlm-12-2021-0511
摘要
Purpose This paper links supply chain risk management to medicine supply chains to explore the role of policymakers in employing supply chain risk management strategies (SCRMS) to reduce generic medicine shortages. Design/methodology/approach Using secondary data supplemented with primary data, the authors map and compare seven countries' SCRMS for handling shortage risks in their paracetamol supply chains before and during the first two waves of the COVID-19 pandemic. Findings Consistent with recent research, the study finds that policymakers had implemented few SCRMS specifically for responding to disruptions caused by COVID-19. However, shortages were largely avoided since multiple strategies for coping with business-as-usual disruptions had been implemented prior to the pandemic. The authors did find that SCRMS implemented during COVID-19 were not always aligned with those implemented pre-pandemic. The authors also found that policymakers played both direct and indirect roles. Research limitations/implications Combining longitudinal secondary data with interviews sheds light on how, regardless of the level of preparedness during normal times, SCRMS can be leveraged to avert shortages in abnormal times. However, the problem is highly complex, which warrants further research. Practical implications Supply chain professionals and policymakers in the healthcare sector can use the findings when developing preparedness and response plans. Social implications The insights developed can help policymakers improve the availability of high-volume generic medicines in (ab)normal times. Originality/value The authors contribute to prior SCRM research in two ways. First, the authors operationalize SCRMS in the medicine supply chain context in (ab)normal times, thereby opening avenues for future research on SCRM in this context. Second, the authors develop insights on the role policymakers play and how they directly implement and indirectly influence the adoption of SCRMS. Based on the study findings, the authors develop a framework that captures the diverse roles of policymakers in SCRM.
科研通智能强力驱动
Strongly Powered by AbleSci AI